Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report.
暂无分享,去创建一个
S. Vasuvattakul | A. Vongwiwatana | B. Cheunsuchon | N. Premasathian | S. Limsrichamrern | T. Sirimongkolrat
[1] V. Sakhuja,et al. Recurrent glomerulopathy in the renal allograft. , 2007, Transplantation proceedings.
[2] L. Gallon,et al. Anti‐CD20 Monoclonal Antibody (Rituximab) for the Treatment of Recurrent Idiopathic Membranous Nephropathy in a Renal Transplant Patient , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] A. Salama,et al. Drug Insight: rituximab in renal disease and transplantation , 2006, Nature Clinical Practice Nephrology.
[4] G. Remuzzi,et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. , 2003, Journal of the American Society of Nephrology : JASN.
[5] E. Briganti,et al. Risk of renal allograft loss from recurrent glomerulonephritis. , 2002, The New England journal of medicine.
[6] L. Racusen,et al. Plasma cell-rich acute renal allograft rejection. , 1999, Transplantation.
[7] J. Thistlethwaite,et al. The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] L. Truong,et al. De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] O. Salvatierra,et al. DE NOVO AND RECURRENT MEMBRANOUS GLOMERULOPATHY FOLLOWING KIDNEY TRANSPLANTATION , 1983, Transplantation.